Study guide
2.5 Lines, Tubes, and Drains in Critical Care
Board Certified Critical Care Pharmacist Study Guide Exam
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: Pathophysiology and Recognition of Critical Illness
1.1 Pathophysiology of Shock and Sepsis 1.2 Respiratory Failure and ARDS Pathophysiology 1.3 ICU-Acquired Weakness and Post-Intensive Care Syndrome 1.4 Chronic Disease States and Risk Factors for Critical Illness
2 Chapter 2: Medical Devices and Circulatory Support
2.1 Hemodynamic Monitoring and Interpretation 2.2 Mechanical Circulatory Support 2.3 Mechanical Ventilation Modes and Settings 2.4 Continuous Renal Replacement Therapy 2.5 Lines, Tubes, and Drains in Critical Care
3 Chapter 3: Fluid, Electrolyte, and Acid-Base Management
3.1 Resuscitation Fluids: Crystalloids vs. Colloids 3.2 Electrolyte Disorders in the ICU 3.3 Acid-Base Disorders and Interpretation
4 Chapter 4: Vasoactive and Inotropic Therapy in Shock
4.1 Vasopressors in Distributive Shock 4.2 Inotropes and Vasopressors in Cardiogenic and Obstructive Shock
5 Chapter 5: Sedation, Analgesia, and Delirium (PADIS)
5.1 Pain and Analgesia in the ICU 5.2 Sedation Strategies and Medication Selection 5.3 Delirium Assessment, Prevention, and Treatment 5.4 Neuromuscular Blockade in Critical Illness
6 Chapter 6: Cardiovascular Emergencies
6.1 Acute Coronary Syndromes in ICU Patients 6.2 Acute Decompensated Heart Failure 6.3 Hypertensive Emergencies and Arrhythmias
7 Chapter 7: Pulmonary and Infectious Diseases in the ICU
7.1 Severe Sepsis and Septic Shock Antimicrobial Selection 7.2 Pharmacotherapy for Mechanical Ventilation and ARDS 7.3 Severe Infections in the ICU
8 Chapter 8: Neurocritical Care
8.1 Ischemic and Hemorrhagic Stroke Management 8.2 Intracranial Hypertension and Brain Edema 8.3 Status Epilepticus and Sedation in Brain Injury
9 Chapter 9: Toxicology, Endocrine, and Hematologic Emergencies
9.1 Toxicology and Antidote Therapy in the ICU 9.2 Endocrine Emergencies 9.3 Hematologic Emergencies, Anticoagulant Reversal, and Transfusions 9.4 Gastrointestinal and Hepatic Emergencies in the ICU 9.5 Dermatologic and Immunologic Conditions in the ICU 9.6 Trauma, Burns, Supportive Care, and End-of-Life Pharmacotherapy
10 Chapter 10: Special Populations, Pharmacokinetics, and Nutrition
10.1 Altered Pharmacokinetics in Critically Ill Patients 10.2 Therapeutic Drug Monitoring in the ICU 10.3 Nutrition Support: Enteral vs. Parenteral
11 Chapter 11: Quality, Safety, and Clinical Guidelines
11.1 Medication Safety and Error Prevention in the ICU 11.2 Antimicrobial Stewardship and Infection Prevention 11.3 Implementation of Clinical Practice Guidelines 11.4 Healthcare Regulations, Standards, and Drug Interactions
12 Chapter 12: Practice Management, Biostatistics, and Evidence-Based Medicine
12.1 ICU Formulary Management and Cost-Effectiveness 12.2 Biostatistics and Literature Evaluation 12.3 Clinical Trial Interpretation in Critical Care 12.4 Professional Development, Precepting, and ICU Pharmacy Services 12.5 Alternative ICU Delivery Models and Disaster Healthcare Management
13 Chapter 13: Treatment Planning and Care Coordination
13.1 Goals of Care, Perioperative Care, and Transitions of Care 13.2 Medication Delivery Routes and Devices in Critical Illness 13.3 Social Determinants of Health and Patient/Caregiver Education
2.5 Lines, Tubes, and Drains in Critical Care
Key Takeaways Explain This Topic AI
Central venous catheters, arterial lines, PA catheters, chest tubes, surgical drains, and feeding tubes each have specific pharmacotherapy implications (anticoagulation, infusion compatibility, drug-drug adsorption, and infection risk).
Central line-associated bloodstream infections (CLABSI) are a National Patient Safety Goal; antimicrobial-impregnated catheters, chlorhexidine dressings, and prompt removal reduce risk.
Drug-catheter adsorption (e.g., nitroglycerin, insulin, furosemide) and infusion line compatibility affect dose delivery and require dedicated lumen assignment in multi-lumen CVCs.
Removal of indwelling devices requires balancing bleeding risk from required anticoagulation (ECMO, CRRT, LVAD) versus thrombosis risk from chronic and acute indications.
Last updated: July 2026
Lines, Tubes, and Drains in Critical Care
The BCCCP Examination Content Outline (1B5) covers lines, tubes, and drains as part of medical therapies and devices. The pharmacist's role centers on anticoagulation management, antimicrobial stewardship for catheter-related infection, infusion compatibility, and drug delivery through altered anatomy.
Vascular Access Device Overview
- Device Indication Pharmacotherapy Implication
- Peripheral IV Short-term access, stable meds Vesicant infusions (vasopressors, chemo) require central access
Central venous catheter (CVC, multi-lumen) Vasopressors, TPN, long-term access Dedicate a lumen to TPN; drug-lumen adsorption (insulin, furosemide)
Antimicrobial-impregnated CVC (chlorhexidine/silver sulfadiazine, minocycline/rifampin) High CLABSI risk Reduces CLABSI; do not substitute for insertion bundle
Tunneled CVC (Hickman, Broviac) Long-term chemotherapy, transplant Lower CLABSI vs. non-tunneled; antimicrobial lock prophylaxis
- PICC Intermediate-term access Vesicant and TPN compatible; thrombosis risk
- Implantable port Oncology, long-term intermittent access Lowest CLABSI; accessed with Huber needle
- Arterial line Continuous BP monitoring, ABG Heparinized or saline flush; risk of retrograde embolism
- Pulmonary artery catheter Hemodynamic profiling in shock Heparin flush; risk of PA rupture, arrhythmia
ECMO cannulae Cardiopulmonary support Systemic anticoagulation (heparin/bivalirudin); drug sequestration in circuit
CRRT catheter Renal replacement therapy Anticoagulation (citrate, heparin); catheter function affects clearance
Other Tubes and Drains
Endotracheal tube: IV access needed; inhaled medications (albuterol, prostacyclin) delivered via ventilator circuit; ensure adequate sedation.
Tracheostomy: reduces ventilator days; consider swallowing dysfunction and aspiration risk when initiating oral medications.
Nasogastric/orogastric tube: medication administration route; verify tube placement; some drugs require intact stomach (e.g., ketoconazole, levothyroxine separation).
Post-pyloric (NJ, Dobhoff) feeding tube: preferred for gastric intolerance or reflux; medication absorption may differ.
Chest tube (tube thoracostomy): pleural drainage; consider chest tube output when dosing renally cleared drugs lost in third spacing.
Surgical drains (JP, hemovac): output affects fluid balance and drug dosing volume.
Urinary catheter: UTI prophylaxis not recommended; monitor for catheter-associated UTI (CAUTI).
Ventriculostomy (EVD): intracranial pressure monitoring; antimicrobial-impregnated catheters reduce EVD infection; antibiotic prophylaxis at insertion only.
CLABSI Prevention and Antimicrobial Lock Therapy
The Society for Healthcare Epidemiology of America (SHEA)/IDSA/APIC strategies:
- Hand hygiene prior to access
- Maximal sterile barrier precautions at insertion
- Chlorhexidine skin antisepsis (>2%)
- Optimal site selection (subclavian preferred over femoral for non-tunneled CVC)
- Daily review of line necessity with prompt removal
- Antimicrobial-impregnated catheters for high-risk patients
- Chlorhexidine-impregnated dressings
Antimicrobial lock therapy for long-term catheters (ethanol 70%, taurolidine, citrate, vancomycin/heparin for high-risk)
Infusion Compatibility and Drug-Catheter Adsorption
Drug adsorption: nitroglycerin, insulin, diazepam, furosemide, amiodarone adsorb to PVC tubing; use non-PVC lines or syringe pumps for sensitive drugs.
Lumen dedication: TPN requires a dedicated lumen; vasopressors may share a lumen; check compatibility charts before Y-site administration.
Alteplase lock: used to restore catheter patency in occluded CVCs; 2 mg dwell for 2 hours.
Anticoagulation Considerations by Device
- Device Anticoagulation Monitoring
- Arterial line Heparinized saline or saline-only flush None routine
- PA catheter Heparinized saline flush None routine
- CRRT Regional citrate (preferred unless citrate toxicity) or systemic heparin Post-filter iCa, ACT/aPTT
- ECMO Systemic heparin (or bivalirudin in HIT) ACT 180-220 or anti-Xa 0.3-0.7 IU/mL
- LVAD Aspirin + warfarin (INR 2-3) INR; avoid dual antiplatelet unless indication
- Drug Delivery Through Altered Anatomy
Tubes and drains change how drugs reach the patient. The pharmacist must verify route compatibility on every order.
Nasogastric/orogastric route: some drugs require an acidic stomach (ketoconazole, itraconazole, levothyroxine, digoxin) and should not be crushed or given with continuous feeds; hold feeds 30 minutes before and after.
Post-pyloric (NJ, Dobhoff) route: avoids stomach, so acid-dependent absorption fails; enteric-coated and extended-release products should not be crushed and may not work post-pylorically.
Do-not-crush list: extended-release, enteric-coated, cytotoxic, hormone, and sustained-release products; crushing causes dose dumping, toxicity, or loss of efficacy.
Rectal route: useful when NPO or upper GI bleed, but absorption unreliable in diarrhea or low cardiac output.
Sublingual/buccal route: preferred for nitroglycerin and lorazepam in shock when IV access is delayed.
Inhaled route via ventilator circuit: albuterol, ipratropium, fluticasone, inhaled nitric oxide, nebulized N-acetylcysteine, and prostacyclin require a vibrating mesh nebulizer placed in the inspiratory limb; drug delivery drops with high humidity and long circuits.
Device Removal and Bleeding/Thrombosis Balance
Removing a device is a pharmacotherapy decision. The pharmacist must weigh thrombosis risk against bleeding risk and time removal to the anticoagulation cycle.
CVC removal: stop any bolus heparin for 1-2 hours; INR <1.8, platelets >50,000.
EVD/ICP monitor removal: reverse coagulopathy; INR <1.4 and platelets >100,000 per neurocritical care guidance.
Chest tube removal: may remove on therapeutic anticoagulation if bleeding is controlled.
ECMO decannulation: high-risk bleeding event; coordinate with surgery and perfusion; pause anticoagulation per protocol.
CRRT catheter removal: remove after stopping citrate/heparin infusion.
Clinical Scenario
A patient on ECMO for ARDS develops catheter-related bloodstream infection. Vancomycin and piperacillin-tazobactam are started. How does the ECMO circuit affect drug delivery, and what monitoring is required?
Answer: The ECMO circuit sequestrates lipophilic drugs (propofol, fentanyl, midazolam) and binds heparin; antibiotic dosing should target higher peaks because of increased Vd. Vancomycin and beta-lactams are less sequestered but require therapeutic drug monitoring with peak/trough or Bayesian dosing given augmented clearance and circuit adsorption. Anticoagulation (heparin or bivalirudin) is titrated to anti-Xa or ACT per institutional protocol. Blood cultures from a peripheral site, not the ECMO circuit, drive de-escalation.